2 weeks Ago By ABMN Staff
Beaird Harris Wealth Management LLC reduced its position in AbbVie Inc. ( NYSE:ABBV – Free Report ) by 2.7% during the second quarter, HoldingsChannel reports.
The fund owned 2,057 shares of the company’s stock after selling 56 shares during the quarter. Beaird Harris Wealth Management LLC’s holdings in AbbVie were worth $353,000 as of its most recent filing with the SEC. Several other institutional investors have also added to or reduced their stakes in ABBV.
Fairway Wealth LLC purchased a new position in shares of AbbVie in the second quarter valued at $26,000. Ridgewood Investments LLC bought a new position in AbbVie in the 2nd quarter worth about $27,000. Vermillion & White Wealth Management Group LLC purchased a new position in AbbVie during the 4th quarter valued at about $26,000.
IFS Advisors LLC bought a new stake in shares of AbbVie during the first quarter valued at about $36,000. Finally, Redmont Wealth Advisors LLC bought a new stake in shares of AbbVie during the first quarter valued at about $37,000. 70.
23% of the stock is owned by hedge funds and other institutional investors. AbbVie Trading Up 1.5 % NYSE ABBV opened at $194.
78 on Friday. The company has a quick ratio of 0.71, a current ratio of 0.
81 and a debt-to-equity ratio of 8.51. The stock’s 50-day simple moving average is $191.
09 and its two-hundred day simple moving average is $176.18. AbbVie Inc.
has a twelve month low of $135.85 and a twelve month high of $199.95.
The company has a market capitalization of $343.96 billion, a price-to-earnings ratio of 57.80, a PEG ratio of 2.
65 and a beta of 0.64. AbbVie Dividend Announcement The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 15th.
Stockholders of record on Tuesday, October 15th will be paid a $1.55 dividend. The ex-dividend date of this dividend is Tuesday, October 15th.
This represents a $6.20 dividend on an annualized basis and a dividend yield of 3.18%.
AbbVie’s dividend payout ratio (DPR) is 183.98%. Insider Activity at AbbVie In other AbbVie news, Chairman Richard A.
Gonzalez sold 66,500 shares of the business’s stock in a transaction on Monday, August 5th. The shares were sold at an average price of $186.52, for a total value of $12,403,580.
00. Following the completion of the sale, the chairman now directly owns 446,599 shares of the company’s stock, valued at $83,299,645.48.
The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website . In related news, Chairman Richard A. Gonzalez sold 282,845 shares of the firm’s stock in a transaction that occurred on Wednesday, July 17th.
The stock was sold at an average price of $175.00, for a total transaction of $49,497,875.00.
Following the transaction, the chairman now directly owns 513,099 shares in the company, valued at approximately $89,792,325. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink . Also, Chairman Richard A.
Gonzalez sold 66,500 shares of the business’s stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $186.52, for a total value of $12,403,580.
00. Following the completion of the sale, the chairman now owns 446,599 shares of the company’s stock, valued at approximately $83,299,645.48.
The disclosure for this sale can be found here . 0.25% of the stock is owned by insiders.
Wall Street Analyst Weigh In Several brokerages recently commented on ABBV. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $200.00 price objective on shares of AbbVie in a research note on Monday, August 5th.
Piper Sandler Companies reissued an “overweight” rating and issued a $190.00 price target on shares of AbbVie in a report on Wednesday, July 3rd. HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and set a $185.
00 price target on the stock in a report on Wednesday, June 5th. BMO Capital Markets increased their price objective on AbbVie from $180.00 to $214.
00 and gave the stock an “outperform” rating in a research report on Friday, July 19th. Finally, Wells Fargo & Company boosted their target price on AbbVie from $200.00 to $205.
00 and gave the stock an “overweight” rating in a research report on Friday, July 26th. Two research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.
com, the stock presently has an average rating of “Buy” and a consensus target price of $191.64. View Our Latest Analysis on AbbVie AbbVie Company Profile ( Free Report ) AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide.
The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. Further Reading Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc.
( NYSE:ABBV – Free Report ). Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter .
.
